CRBN and Miyoshi myopathy: Lenalidomide, an IMiD having the CBRL (cereblon) protein as the target for its anti-neoplastic activities, represents a key component of most first-line multi-agent regimens, both in transplant-eligible patients, as a part of induction treatment (VRd) and/or in maintenance therapy following ASCT, and in transplant-ineligible MM patients (VRd, Rd, and DRd) [18].